Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes

By  

Current Diabetes Reviews, Vol. 6, Iss. 4, 2010-07 ,pp. : 191-200

Bentham Science Publishers

Access to resources Recommend Favorite

Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes

By Setji Tracy   Feinglos Mark  

Expert Review of Endocrinology and Metabolism, Vol. 8, Iss. 3, 2013-05 ,pp. : 229-238

Informa Healthcare

Access to resources Recommend Favorite

Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

By  

Current Diabetes Reviews, Vol. 3, Iss. 1, 2007-01 ,pp. : 15-23

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists

By  

Current Diabetes Reviews, Vol. 5, Iss. 4, 2009-11 ,pp. : 266-275

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

By  

Current Vascular Pharmacology, Vol. 14, Iss. 5, 2016-09 ,pp. : 469-473

Bentham Science Publishers

Access to resources Recommend Favorite